Update on infliximab: an intravenous biologic therapy for psoriasis

References

• Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin. Exp. Dermatol.26(4), 314–320 (2001).
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm. Venereol.80(6), 430–434 (2000).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol.41(3 Pt 1), 401–407 (1999).
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J. Dermatolog. Treat.17(1), 24–28 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin. Pharmacother.4(9), 1525–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Stern RS. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J. Am. Acad. Dermatol.49(3), 445–450 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol.137(3), 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med.356(6), 580–592 (2007).
   PubMed Web of Science ®Google Scholar
• Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am. J. Med.107(6), 595–605 (1999).
   PubMed Web of Science ®Google Scholar
• Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am. Fam. Physician61(3), 725–733, 736 (2000).
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J. Am. Acad. Dermatol.41(3 Pt 2), S25–S28 (1999).
   PubMed Web of Science ®Google Scholar
• Feldman S. Advances in psoriasis treatment. Dermatol. Online J.6(1), 4 (2000).
   PubMedGoogle Scholar
• Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J. Am. Acad. Dermatol.41(5 Pt 1), 728–732 (1999).
   PubMed Web of Science ®Google Scholar
• Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch. Dermatol.142(7), 836–842 (2006).
   PubMedGoogle Scholar
• Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med.349(7), 658–665 (2003).
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost–effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J. Dermatolog. Treat.17(1), 29–37 (2006).
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol.55(5), 829–835 (2006).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA296(14), 1735–1741 (2006).
   PubMed Web of Science ®Google Scholar
• Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br. J. Dermatol.139(1), 88–95 (1998).
   PubMed Web of Science ®Google Scholar
• Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol.36(3 Pt 1), 423–432 (1997).
   PubMed Web of Science ®Google Scholar
• Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J. Am. Acad. Dermatol.44(4), 643–651 (2001).
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J. Dermatolog. Treat.17(2), 96–107 (2006).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152(6), 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol.55(4), 598–606 (2006).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366(9494), 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An International, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol.139(6), 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA290(23), 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol.30(16), 1443–1453 (1993).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7(3), 251–259 (1995).
   PubMed Web of Science ®Google Scholar
• Centocor. Remicade (infliximab), package insert (2007).
   Google Scholar
• Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum.54(3), 711–715 (2006).
   PubMed Web of Science ®Google Scholar
• Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol.33(1), 31–36 (2006).
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum.54(12), 3782–3789 (2006).
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br. J. Dermatol.156(2), 329–336 (2007).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.51(4), 534–542 (2004).
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol.56(1), 31–15 (2007).
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.52(4), 1227–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin. Gastroenterol. Hepatol.5(6), 729–735 (2007).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.44(2), 265–267 (2007).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA295(19), 2275–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J. Am. Acad. Dermatol.56(1), e55–e79 (2007).
   PubMedGoogle Scholar
• Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br. J. Dermatol.152(5), 954–960 (2005).
   PubMed Web of Science ®Google Scholar